CA-NTTVC
26.10.2020 12:42:10 CET | Business Wire | Press release
NTTVC today publicly announced its $500 million fund to help startups reach rapid global scale by harnessing the power of partnership. The independent venture capital firm was founded by entrepreneur and investor Vab Goel in collaboration with global technology service provider NTT . The firm is also announcing investments in five startups delivering impactful innovations for businesses and consumers: Celona , Eko , nference , Shoreline and UDP Labs .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005262/en/
NTTVC invests broadly across all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. By combining the deep relationships of its investment team with the reach of NTT, the firm offers access to a robust network of industry experts, customers, entrepreneurs, business leaders, system integrators and service providers who can help startups make better decisions, more quickly.
NTT is a $109 billion, top five global technology service provider serving 75 million mobile subscribers, 3 million businesses and 120,000 enterprise customers with a local presence in over 80 countries. The company has a long history of embracing startups and helping them achieve global scale. By partnering with Goel to form a returns-driven venture capital fund, NTT deepens its commitment to building long-term relationships in the entrepreneurial ecosystem. In turn, NTTVC portfolio companies have the choice and opportunity to sell to, through and with NTT to help scale their businesses.
“Our mission is to use technology for good to solve social challenges for people, clients and communities,” said Jun Sawada, President and CEO of NTT Corporation. “We have always believed that the startup ecosystem is essential to delivering on that promise, which is why we chose to partner with NTTVC to fuel the next generation of world-changing technologies.”
Collectively, the NTTVC team has founded, advised, scaled and invested in over a hundred startups. Their drive for supporting entrepreneurs stems from their direct experiences as founders and venture capitalists. Prior to founding NTTVC, Goel was a Partner at Norwest Venture Partners for 19 years and helped build many of the foundational technologies of today’s Internet as an entrepreneur, venture capitalist and technologist. Partner Fay Hazaveh Costa worked closely with Goel at Norwest Venture Partners and previously helped launch Hewlett Packard Enterprise’s venture group. Mike Koenig, Portfolio Development Partner, is a seasoned sales and business development leader who was an early executive at two startups backed by Goel. Koenig supports NTTVC portfolio companies through impactful connections with the firm’s network.
“We are still in the early innings of a digital transformation that is affecting every industry and creating unprecedented opportunities for startups,” said Vab Goel. “We are passionate about teaming up with entrepreneurs through every phase of their journey to build impactful companies.”
“NTTVC offers entrepreneurs the best of both worlds: an independent and agile investment model coupled with the unique access to our global network,” said Fay Hazaveh Costa. “This powerful combination gives startups a true competitive advantage in scaling and realizing their vision.”
For more information read the firm’s blog post and visit nttvc.com .
About NTTVC
NTTVC is an independent venture capital firm formed in collaboration with NTT. Leveraging a unique partnership-focused strategy and deep industry network, NTTVC unlocks doors to relationships that can help startups reach global scale. With its $500M inaugural fund, the firm invests broadly in technology startups of all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. NTTVC is headquartered in Silicon Valley. Learn more at nttvc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005262/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom